Several groups are studying the modulation of the PI3K/AKT pathway as a promising strategy to overcome resistance to EGFR pathway-based therapies in NSCLC, considering the several shared downstream effectors common to the two signaling networks. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.